What is Moximed?
Founded in 2006, Moximed specializes in the design and manufacturing of advanced surgical equipment tailored for the treatment of osteoarthritis. The company occupies a unique market position by focusing on joint-preserving solutions that offer alternatives to traditional total joint replacement surgeries. By addressing the needs of patients who are not yet candidates for invasive procedures, Moximed has established a high-barrier-to-entry niche within the medical technology sector. Its operational focus remains on improving patient mobility and quality of life through innovative, biomechanically sound interventions that align with the broader shift toward minimally invasive orthopedic care.
How much funding has Moximed raised?
Moximed has raised a total of $239.8M across 6 funding rounds:
Private Equity
$10M
Series A
$45.8M
Series B
$33M
Series C
$50M
Series C
$40M
Series D
$61M
Private Equity (2009): $10M, investors not publicly disclosed
Series A (2011): $45.8M led by Gilde Healthcare, Frazier Healthcare Partners, and GBS Venture Partners
Series B (2015): $33M supported by Gilde Healthcare, Morgenthaler Private Equity, New Enterprise Associates, Vertex Holdings, and GBS Venture Partners
Series C (2017): $50M featuring Gilde Healthcare, Vertex Healthcare, Morgenthaler Private Equity, Advent Venture Partners, NEA, and GBS Venture Partners
Series C (2022): $40M backed by Future Fund, Advent Life Sciences, Vertex Healthcare, New Enterprise Associates, Gilde Healthcare, and GBS Venture Partners
Series D (2024): $61M with participation from New Enterprise Associates, Gilde Healthcare, and Elevage Medical Technologies
Key Investors in Moximed
Gilde Healthcare
A specialized healthcare investment firm managing over 1.4 billion euros across venture, growth, and private equity strategies, focusing on impactful solutions that enable better care at lower costs.
New Enterprise Associates
A prominent venture capital firm established in 1977 that provides extensive operational support and capital to entrepreneurs building transformative businesses in the healthcare and technology sectors.
Elevage Medical Technologies
A strategic investor dedicated to supporting medical technology companies, including diagnostics and devices, that aim to improve patient health outcomes through capital and operational expertise.
What's next for Moximed?
With the successful closure of this latest funding round, Moximed is poised to scale its commercial operations and deepen its clinical evidence base. The strategic backing from a consortium of seasoned healthcare investors provides the necessary runway to navigate complex regulatory pathways and expand its footprint in both domestic and international markets. Future growth will likely center on the commercialization of its core product pipeline and the potential for further technological integration, ensuring that the company remains at the forefront of the orthopedic innovation cycle. As the firm transitions into this next phase of maturity, the focus will shift toward achieving sustainable market penetration and long-term value creation for its stakeholders.
See full Moximed company page
